Ray Cameron Email & Phone Number

Sutton, Gb

Brentford, Middlesex, Gb

• Nov 2021 to Dec 2023: Clinical Development Director. Clinical Science Lead, Oncology, New opportunities and pipeline development: Provided clinical development expertise and scientific input into the integrated evaluation and due diligence of potential in-licensing and partnering opportunities across a range of oncology indications, MOA and platforms.• May 2020 to Nov 2021: Clinical Development Director. Clinical Science Lead on several late development programs in GI and Hepatology.• Achievements at the global project level include significant, input into in the strategic development of a number of assets, Ensuring alignment with project strategy, regulatory requirements and commercial goals. At the study level included providing effective support / oversight of clinical studies to assure patient safety and study delivery. • Contributed to regulatory interactions including briefing documents, and addressing questions and responses.• Jul 2016 to Apr 2020, Discovery Medicines Scientist Director: Neuroscience. Clinical Science Lead on several early development programs indicated for neurodegenerative diseases e.g.: Amyotrophic Lateral Sclerosis, Alzheimer ’s disease, Huntington’s, Parkinson’s and optic neuropathies • Achievements included providing clinical support and input into GSK’s Research Units end to end integrated clinical development strategy for the above assets : indication selection/prioritization, scientific engagement, early translational plans and biomarker strategies and the development and execution of FTIH/ experimental medicine protocols. Preparation of documents to support for Governance milestones.• Jul 2014 to Jun 2016, Clinical Development Director, Neuroscience TA Leading role in the Ofatumumab Relapsing Remitting Multiple Sclerosis program: reporting phase II/planning phase III pivotal studies. Clinical input into the paediatric plan for MS.

Basel, Baselstadt, Ch

• Successfully led cross-functional International Clinical Teams accountable for the design and planning of complex phase II to III global clinical development programs, to support global marketing approvals, for 6 new compounds with novel mechanisms of action (e.g. monoclonal antibodies). • As the global clinical representative, worked collaboratively with Global Program Team, for the definition of aligned strategy - clinical phases I through to III.• Provided major input into the development of Target Product Profiles and clinical development plans.• Prepared briefing books (BB), clinical representative at two FDA pre-IND meetings and EMEA, FDA and Canadian end of phase II meetings. Fully engaged in discussion/negotiation with committee members. Input into several BB for other health authority meetings • Subject matter expert - presented data from clinical studies and programs at numerous diverse internal/external meetings: international congresses, advisory boards, health economics and pricing, medical marketing and investigators meetings.• Clinical trial leader for numerous global clinical studies. Designed, developed and wrote protocols (Sole responsibility), planned, executed, analyzed/interpreted study results and wrote reports prepared abstracts and publications and presented results at major respiratory congresses e.g. ATS and ERS.• Proven ability to plan, supervise and manage resource and significant budgets – successfully led the activities of a clinical team (>6 medics and clinical scientist) in all aspects of planning, execution, interpretation, reporting of one of the largest and most complex studies the Novartis Respiratory Therapeutic Area had ever undertaken, >3,500 patients, 400 sites, 40 countries, with an external budget >$50 million. • Played a leading role on the project team that successfully achieved marketing approval for Indacterol. My involvement spanned phase I through to marketing approval in over 80 countries.

Successfully led cross functional project teams responsible for all aspects of development: designing, implementing, running and reporting a number of protocols for phase III/b asthma, single center and multi center multinational trials

London, Gb